/stocks — the workspaceLOADING
Merck depends heavily on Keytruda, a cancer immunotherapy that accounts for over 40% of sales and loses key US patent protection in 2028. Gardasil HPV vaccines and an animal health unit round out the business.
Merck & Co., Inc. (MRK) is a pharmaceutical preparations company. Piotroski F-Score 3/7. 40 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-07-28 from MRK's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Led by Robert Davis · see pay & career →
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
A plain-English read on MRK plus an auto-SWOT — built from MRK's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate MRK using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Fisher Asset Management (Ken Fisher) | $3.18B | 1.1% of portfolio |
Projected from MRK's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment MRK files its announcement.
MRK has sold off after 5 of its last 8 earnings reports.
Earnings reactions have been moderate.
MRK has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+5.1% and -11.5%).
A more typical earnings reaction has been approximately ±3.6%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-04-30 | +1.1% |
| 2026-02-03 | +4.4% |
| 2025-10-30 | -0.7% |
| 2025-07-29 | -2.7% |
| 2025-04-24 | +5.1% |
| 2025-02-04 | -10.1% |
| 2024-10-31 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -2.8% |
| 2024-07-30 | -11.5% |
| Company | Stake value | % of company owned |
|---|---|---|
| MODERNA INCMRNA | $117.3M | 0.58% |
| PERSONALIS INCPSNL | $89.5M | 13.4% |
| KYMERA THERAPEUTICS INCKYMR | $64.3M | 0.94% |
| ENTRADA THERAPEUTICS INCTRDA | $22.0M | 4.5% |
| EIKON THERAPEUTICS INCEIKN | $17.6M | 3.1% |
| AKTIS ONCOLOGY INCAKTS | $17.0M | — |
| ALECTOR INCALEC | $7.6M | 3.2% |
| SUTRO BIOPHARMA INCSTRO | $6.8M | 1.6% |
| EVAXION BIOTECH A/S | $4.5M | — |
| VIRIDIAN THERAPEUTICS INC | $1.8M | — |
| XILIO THERAPEUTICS INCXLO | $891K | 1.8% |
| CARISMA THERAPEUTICS INC | $48K | — |
| NEUPHORIA THERAPEUTICS INCNEUP | $41K | 0.19% |
| TUHURA BIOSCIENCES | $35K | — |
Long US equity positions from MRK's own 13F-HR (SEC), reported quarterly and lagged up to 45 days. “% of company owned” = reported shares ÷ that company's latest shares outstanding.